SARS-CoV-2 vaccine: Clinical trial phase to begin soon
Again and again, it is pointed out that the danger will be averted by the Coronavirus SARS-CoV-2 only, if there is a vaccination against the novel pathogen is available. Now, researchers from Germany report that, in a few months, clinical trials for a vaccine against the Coronavirus can start.
More and more people are wondering what time is the first vaccine will be against the new Coronavirus is available. Worldwide, researchers work on vaccines at the end of. Such as the German centre for infection research (DZIF) reported now, is currently producing a vaccine for the clinical trial phase.
Blueprint for the vaccine is already finished
According to a communication of the DZIF this year, a potential vaccine against SARS should-CoV-2 in the first clinical trials to be tested on humans.
“The Blueprint for the vaccine is ready. Now, the vaccine has to be produced for the clinical Tests,” explains Prof. Dr. Stephan Becker, Director of the Institute for Virology at the University of Marburg and coordinator of the area of “emerging infectious diseases” in the DZIF.
“We have now, financially and logistically, everything, to start soon in a Phase I clinical testing,” adds the expert.
The information suggests that the Tests in this Phase, compatibility, and stimulation of immune responses. In Marburg the is held Immune Monitoring, i.e., the characterization of the antibody response to the vaccine.
Vaccine approval takes a longer period of time
Currently, the vaccine is made for a Phase I clinical trial. According to the report, production is expected to be concluded in three months, so the clinical trials can start in September.
Although the development of running in comparison to the previous method is much faster, is this year still no vaccine available. “The development of a vaccine is a lengthy, arduous process, especially the clinical exam for the admission of a candidate. That is not possible in a couple of weeks,“ explains Becker.
Now for the Phase I clinical upcoming vaccine candidate was developed under the leadership of Prof. Dr. Gerd Sutter, Ludwig-Maximilians-University (LMU) in Munich.
It is a so-called vector vaccine, based on the “Modified vaccinia virus Ankara” (MVA) as a vector. The Vaccine virus MVA has already generated over 30 years ago at the LMU as a vaccine against smallpox. The MVA viruses are so attenuated that they can serve as a harmless vectors for other vaccines.
Those interested can register
“We have a platform technology and can, in principle, any foreign genetic Information under the control of the Vaccine virus. It is a proven vector system for the large-scale production is already established,“ said Sutter.
The base virus is fully characterized and, together with genetically modified varieties of more than 12,000 people have been clinically tested. We know the side effect profile and the immunogenicity of the basic vaccine very well,“ explains the expert.
This vector was used in the DZIF is already successfully for the development of a vaccine against the MERS-Coronavirus, a close relative of the SARS-CoV 2; the first clinical testing of this MERS vaccine has already been completed and further clinical development is currently ongoing.
According to the report, the clinical examination by prof Marylyn Addo will be managed by the University hospital Hamburg-Eppendorf (UKE). “For many of the procedures in this development process, the experience of the MVA-MERS can be used study as a blueprint,” says Addo.
“For the new vaccine, the regulatory preparation for the clinical examination has already begun. An official recruitment of subjects can only be made after obtaining a positive vote of the ethics Commission, however, interested parties can already, under the E-Mail [email protected] to register.“
Man is to form antibodies
Crucial for the effect of the vaccine against SARS-CoV-2, the components of the Virus against which the human antibody will form, according to the experts. The researchers of the Spike have to be an appropriate Coronavirus-component Protein on the surface of the Virus selected.
As the scientists explain, and scientists, this Protein is important for the Penetration of the Virus into the human cell. The corresponding gene sequence, the Blueprint of this Protein, was combined with the genetic Information of the MVA vector.
According to the figures, the resulting Vaccine virus penetrates then in the case of a vaccine into the cells, and synthesized the Spike Protein, which is recognized by the immune system as “foreign” and thus the immune response is stimulated. Specific antibodies and T cells against the Spike are formed of Protein, to combat a subsequent infection with the pathogen. (ad)